Creative Planning Purchases 16,157 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Creative Planning increased its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 22.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,522 shares of the company's stock after acquiring an additional 16,157 shares during the quarter. Creative Planning owned about 0.05% of Dr. Reddy's Laboratories worth $6,668,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RDY. Jane Street Group LLC increased its stake in shares of Dr. Reddy's Laboratories by 2,197.8% in the first quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock worth $8,301,000 after purchasing an additional 108,243 shares during the period. BNP Paribas Financial Markets increased its position in Dr. Reddy's Laboratories by 46.9% in the 1st quarter. BNP Paribas Financial Markets now owns 103,259 shares of the company's stock worth $7,574,000 after buying an additional 32,958 shares during the period. OLD Mission Capital LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 66.2% during the first quarter. OLD Mission Capital LLC now owns 47,537 shares of the company's stock worth $3,487,000 after buying an additional 18,930 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its position in shares of Dr. Reddy's Laboratories by 11.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 62,177 shares of the company's stock valued at $4,561,000 after acquiring an additional 6,322 shares during the period. Finally, Frank Rimerman Advisors LLC acquired a new stake in shares of Dr. Reddy's Laboratories in the second quarter worth $2,633,000. Institutional investors and hedge funds own 14.02% of the company's stock.

Wall Street Analyst Weigh In

Separately, Barclays increased their price target on shares of Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the company an "overweight" rating in a report on Tuesday, July 30th.

Dr. Reddy's Laboratories Stock Performance

Dr. Reddy's Laboratories stock traded up $0.28 during trading hours on Thursday, hitting $79.57. The stock had a trading volume of 161,331 shares, compared to its average volume of 215,010. The company has a 50-day moving average of $81.17 and a two-hundred day moving average of $75.92. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a fifty-two week low of $63.72 and a fifty-two week high of $84.46. The company has a market cap of $13.28 billion, a PE ratio of 19.71, a price-to-earnings-growth ratio of 1.75 and a beta of 0.55.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.10). The firm had revenue of $919.80 million during the quarter, compared to analyst estimates of $861.68 million. Dr. Reddy's Laboratories had a net margin of 19.28% and a return on equity of 20.32%. On average, equities research analysts anticipate that Dr. Reddy's Laboratories Limited will post 4.11 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.